Kira Biotech

Kira Biotech is an Australian biotechnology company focused on developing innovative immunomodulatory compounds for treating immune system disorders. The company's lead candidate, KB312, is a first-in-class monoclonal antibody designed to selectively deplete activated immune cells, aiming to restore immune balance by inducing tolerance. Kira Biotech is currently advancing KB312 through preclinical development and phase 1 clinical trials, supported by a team of experienced drug development professionals, including Dr. Dan Baker, a prominent rheumatologist and immunologist. The company has successfully secured venture capital funding to support its research and development efforts.